These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

718 related items for PubMed ID: 14701989

  • 1. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10.
    Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C.
    Invest Radiol; 2004 Jan; 39(1):56-63. PubMed ID: 14701989
    [Abstract] [Full Text] [Related]

  • 2. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil.
    Jung CW, Jacobs P.
    Magn Reson Imaging; 1995 Jan; 13(5):661-74. PubMed ID: 8569441
    [Abstract] [Full Text] [Related]

  • 3. Atorvastatin and uptake of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) in human monocyte-macrophages: implications for magnetic resonance imaging.
    Müller K, Skepper JN, Tang TY, Graves MJ, Patterson AJ, Corot C, Lancelot E, Thompson PW, Brown AP, Gillard JH.
    Biomaterials; 2008 Jun; 29(17):2656-62. PubMed ID: 18377983
    [Abstract] [Full Text] [Related]

  • 4. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro.
    Müller K, Skepper JN, Posfai M, Trivedi R, Howarth S, Corot C, Lancelot E, Thompson PW, Brown AP, Gillard JH.
    Biomaterials; 2007 Mar; 28(9):1629-42. PubMed ID: 17178155
    [Abstract] [Full Text] [Related]

  • 5. Role of carbohydrate receptors in the macrophage uptake of dextran-coated iron oxide nanoparticles.
    Chao Y, Karmali PP, Simberg D.
    Adv Exp Med Biol; 2012 Mar; 733():115-23. PubMed ID: 22101717
    [Abstract] [Full Text] [Related]

  • 6. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors.
    Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, Cohen JI, Petrillo A, Rink D, Neuwelt EA.
    AJNR Am J Neuroradiol; 2002 Apr; 23(4):510-9. PubMed ID: 11950637
    [Abstract] [Full Text] [Related]

  • 7. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.
    Yancy AD, Olzinski AR, Hu TC, Lenhard SC, Aravindhan K, Gruver SM, Jacobs PM, Willette RN, Jucker BM.
    J Magn Reson Imaging; 2005 Apr; 21(4):432-42. PubMed ID: 15779033
    [Abstract] [Full Text] [Related]

  • 8. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics.
    Lutz AM, Weishaupt D, Persohn E, Goepfert K, Froehlich J, Sasse B, Gottschalk J, Marincek B, Kaim AH.
    Radiology; 2005 Mar; 234(3):765-75. PubMed ID: 15665219
    [Abstract] [Full Text] [Related]

  • 9. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil.
    Jung CW.
    Magn Reson Imaging; 1995 Mar; 13(5):675-91. PubMed ID: 8569442
    [Abstract] [Full Text] [Related]

  • 10. [Labeling of mesenchymal stem cells with different superparamagnetic particles of iron oxide and detectability with MRI at 3T].
    Ittrich H, Lange C, Dahnke H, Zander AR, Adam G, Nolte-Ernsting C.
    Rofo; 2005 Aug; 177(8):1151-63. PubMed ID: 16021549
    [Abstract] [Full Text] [Related]

  • 11. Scavenger receptor-AI-targeted iron oxide nanoparticles for in vivo MRI detection of atherosclerotic lesions.
    Segers FM, den Adel B, Bot I, van der Graaf LM, van der Veer EP, Gonzalez W, Raynal I, de Winther M, Wodzig WK, Poelmann RE, van Berkel TJ, van der Weerd L, Biessen EA.
    Arterioscler Thromb Vasc Biol; 2013 Aug; 33(8):1812-9. PubMed ID: 23744990
    [Abstract] [Full Text] [Related]

  • 12. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging.
    Arbab AS, Bashaw LA, Miller BR, Jordan EK, Lewis BK, Kalish H, Frank JA.
    Radiology; 2003 Dec; 229(3):838-46. PubMed ID: 14657318
    [Abstract] [Full Text] [Related]

  • 13. Physical and biological characterization of superparamagnetic iron oxide- and ultrasmall superparamagnetic iron oxide-labeled cells: a comparison.
    Sun R, Dittrich J, Le-Huu M, Mueller MM, Bedke J, Kartenbeck J, Lehmann WD, Krueger R, Bock M, Huss R, Seliger C, Gröne HJ, Misselwitz B, Semmler W, Kiessling F.
    Invest Radiol; 2005 Aug; 40(8):504-13. PubMed ID: 16024988
    [Abstract] [Full Text] [Related]

  • 14. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro.
    Metz S, Bonaterra G, Rudelius M, Settles M, Rummeny EJ, Daldrup-Link HE.
    Eur Radiol; 2004 Oct; 14(10):1851-8. PubMed ID: 15249981
    [Abstract] [Full Text] [Related]

  • 15. Factors regulating macrophage endocytosis of nanoparticles: implications for targeted magnetic resonance plaque imaging.
    Rogers WJ, Basu P.
    Atherosclerosis; 2005 Jan; 178(1):67-73. PubMed ID: 15585202
    [Abstract] [Full Text] [Related]

  • 16. In vivo leukocyte labeling with intravenous ferumoxides/protamine sulfate complex and in vitro characterization for cellular magnetic resonance imaging.
    Wu YJ, Muldoon LL, Varallyay C, Markwardt S, Jones RE, Neuwelt EA.
    Am J Physiol Cell Physiol; 2007 Nov; 293(5):C1698-708. PubMed ID: 17898131
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Labeling efficacy of superparamagnetic iron oxide nanoparticles to human neural stem cells: comparison of ferumoxides, monocrystalline iron oxide, cross-linked iron oxide (CLIO)-NH2 and tat-CLIO.
    Song M, Moon WK, Kim Y, Lim D, Song IC, Yoon BW.
    Korean J Radiol; 2007 Nov; 8(5):365-71. PubMed ID: 17923778
    [Abstract] [Full Text] [Related]

  • 19. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency.
    Matuszewski L, Persigehl T, Wall A, Schwindt W, Tombach B, Fobker M, Poremba C, Ebert W, Heindel W, Bremer C.
    Radiology; 2005 Apr; 235(1):155-61. PubMed ID: 15749976
    [Abstract] [Full Text] [Related]

  • 20. Feraheme (Ferumoxytol) Is Recognized by Proinflammatory and Anti-inflammatory Macrophages via Scavenger Receptor Type AI/II.
    Wang G, Serkova NJ, Groman EV, Scheinman RI, Simberg D.
    Mol Pharm; 2019 Oct 07; 16(10):4274-4281. PubMed ID: 31556296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.